Inflammatory bowel disease: clinical aspects and established and evolving therapies

Lancet

Volumn 369, Issue 9573, 2007, Pages 1641-1657

  Baumgart, Daniel C ^a   Sandborn, William J ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABT 874; ADALIMUMAB; ALICAFORSEN; ANTIBIOTIC AGENT; AST 120; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE; BUDESONIDE; CERTOLIZUMAB PEGOL; CNT 01275; CORTICOSTEROID; CYCLOSPORIN A; DORAMAPIMOD; ETANERCEPT; GOLIMUMAB; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 10; KGF 2; LIALDA; MERCAPTOPURINE; MESALAZINE; MESAVANT; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 02; NATALIZUMAB; OLSALAZINE; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; RECOMBINANT GROWTH FACTOR; SALAZOSULFAPYRIDINE; SEMAPIMOD; SMALL MOLECULE TRANSPORT AGENT; STA 5326; TETOMILAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ACNE; ALGORITHM; ANAPHYLAXIS; ARTHRALGIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BONE NECROSIS; CANCER RISK; CATARACT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CROHN DISEASE; DEMYELINATING DISEASE; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; ECCHYMOSIS; ENDOCRINE DISEASE; ENTERITIS; FEVER; GINGIVA HYPERPLASIA; GLAUCOMA; HEADACHE; HEPATITIS; HIRSUTISM; HISTORY; HUMAN; HYPERPLASIA; HYPERSENSITIVITY; HYPERTENSION; INFECTION; INFECTION RISK; INFLAMMATORY CELL; INJECTION SITE REACTION; INTESTINE FLORA; KIDNEY FAILURE; LEUKAPHERESIS; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FIBROSIS; LUNG FIBROSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MALAISE; META ANALYSIS; MOON FACE; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; MYOPATHY; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PATHOLOGY; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RASH; REMISSION; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SOLID TUMOR; STRIA; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; VEIN OCCLUSION;

EID: 34248136340     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60751-X     Document Type: Review

References (163)

1. Baumgart D., and Carding S. Inflammatory bowel disease: cause and immunobiology. Lancet 369 (2007) 1627-1640
2. Thielman N., and Guerrant R. Clinical practice: acute infectious diarrhoea. N Engl J Med 350 (2004) 38-47
3. Carter M., Lobo A., and Travis S. Ibd Section BSoG, Guidelines for the management of inflammatory bowel disease in adults. Gut 53 suppl 5 (2004) V1-V16
4. Kornbluth A., and Sachar D. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 99 (2004) 1371-1385
5. D'Haens G., Sandborn W., Feagan B., et al. A review of activity indices and efficacy endponts for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007) 763-786
6. Langholz E., Munkholm P., Davidsen M., and Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 (1994) 3-11
7. Langholz E., Munkholm P., Davidsen M., Nielsen O., and Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 31 (1996) 260-266
8. Winther K., Jess T., Langholz E., Munkholm P., and Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 125 (2003) 1576-1582
9. Sandborn W., and Hanauer S. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 29-42
10. Sutherland L., May G., and Shaffer E. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118 (1993) 540-549
11. Kruis W., Bar-Meir S., Feher J., et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1 (2003) 36-43
12. Hanauer S., Sandborn W., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100 (2005) 2478-2485
13. Kamm M., Sandborn W., Gassull M., et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007) 66-75
14. Baron J., Connell A., Lennard-Jones J., and Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1 (1962) 1094-1096
15. Misiewicz J., Lennard-Jones J., Connell A., Baron J., and Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1 (1965) 185-188
16. Williams C. Efficacy and tolerance of 5-aminosalicyalic acid suppositories in the treatment of ulcerative procititis: a review of two double-blind, placebo-controlled trials. Can J Gastroenterol 4 (1990) 472-475
17. Hanauer S., Good L., Goodman M., et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 95 (2000) 1749-1754
18. Sutherland L., Martin F., Greer S., et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92 (1987) 1894-1898
19. Marteau P., Probert C., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 (2005) 960-965
20. Sninsky C., Cort D., Shanahan F., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 115 (1991) 350-355
21. Hanauer S., Schwartz J., Robinson M., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88 (1993) 1188-1197
22. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298 (1989) 82-86
23. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 124 (1996) 204-211
24. Miner P., Hanauer S., Robinson M., Schwartz J., and Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 40 (1995) 296-304
25. Feurle G., Theuer D., Velasco S., et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 30 (1989) 1354-1361
26. Sandberg-Gertzen H., Jarnerot G., and Kraaz W. Azodisal sodium in the treatment of ulcerative colitis: a study of tolerance and relapse-prevention properties. Gastroenterology 90 (1986) 1024-1030
27. Levine D., Riff D., Pruitt R., et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 97 (2002) 1398-1407
28. Giaffer M., Holdsworth C., Lennard-Jones J., et al. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day. Aliment Pharmacol Ther 6 (1992) 479-485
29. Truelove S., and Hambling M. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. BMJ 14 (1958) 1072-1077
30. Hanauer S., Robinson M., Pruitt R., et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 115 (1998) 525-532
31. Truelove S., and Witts L. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 2 (1955) 1041-1048
32. Baron J., Connell A., Kanaghinis T., Lennard-Jones J., and Jones A. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ 5302 (1962) 441-443
33. Lennard-Jones J., Misiewicz J., Connell A., Baron J., and Jones F. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 191 (1965) 188-189
34. Truelove S., and Jewell D. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1 (1974) 1067-1070
35. Jewell D., and Truelove S. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. BMJ 4 (1974) 627-630
36. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., and Bianchi Porro G. Randomised, controlled trial, of azathioprine and 5-aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut 55 (2006) 47-53
37. Hawthorne A., Logan R., Hawkey C., et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305 (1992) 20-22
38. Lichtiger S., Present D., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
39. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 (2003) 1025-1031
40. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 (2006) 1255-1262
41. Rutgeerts P., Sandborn W., Feagan B., et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
42. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
43. Scholmerich J. Systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther 20 suppl 4 (2004) 66-74
44. Marshall J., and Irvine E. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40 (1997) 775-781
45. Lichtenstein G., Abreu M., Cohen R., Tremaine W., and American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
46. Faubion W., Loftus E., Harmsen W., Zinsmeister A., and Sandborn W. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
47. D'Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120 (2001) 1323-1329
48. Baumgart D., Wiedenmann B., and Dignass A. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17 (2003) 1273-1281
49. Oren R., Arber N., Odes S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 (1996) 1416-1421
50. Berg D., Bahadursingh A., Kaminski D., and Longo W. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 184 (2002) 45-51
51. Larson D., and Pemberton J. Current concepts and controversies in surgery for IBD. Gastroenterology 126 (2004) 1611-1619
52. Itzkowitz S., and Present D. Crohn's Colitis Foundation of America Colon Cancer in IBDSG. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 314-321
53. Hueting W., Buskens E., van der Tweel I., Gooszen H., and van Laarhoven C. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9317 patients. Dig Surg 22 (2005) 69-79
54. Gasche C., Scholmerich J., Brynskov J., et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6 (2000) 8-15
55. Silverberg M., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 suppl A (2005) 5-36
56. Louis E., Collard A., Oger A., Degroote E., Aboul Nasr El Yafi F., and Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49 (2001) 777-782
57. Hanauer S., and Sandborn W. The Practice Parameters Committee of the American College of Gastroenterology: management of Crohn's disease in adults. Am J Gastroenterol 96 (2001) 635-643
58. Travis S., Stange E., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 suppl 1 (2006) i16-i35
59. Sandborn W., Feagan B., Hanauer S., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
60. Loftus Jr. E., Schoenfeld P., and Sandborn W. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 16 (2002) 51-60
61. Munkholm P., Langholz E., Davidsen M., and Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30 (1995) 699-706
62. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 8 (2002) 244-250
63. Jess T., Winther K., Munkholm P., Langholz E., and Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 122 (2002) 1808-1814
64. Summers R., Switz D., Sessions Jr. J., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 (1979) 847-869
65. Malchow H., Ewe K., Brandes J., et al. European Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 86 (1984) 249-266
66. Tremaine W., Schroeder K., Harrison J., and Zinsmeister A. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 19 (1994) 278-282
67. Singleton J., Hanauer S., Gitnick G., et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 104 (1993) 1293-1301
68. Hanauer S., and Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2 (2004) 379-388
69. Ewe K., Herfarth C., Malchow H., and Jesdinsky H. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42 (1989) 224-232
70. Camma C., Giunta M., Rosselli M., and Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta- analysis adjusted for confounding variables. Gastroenterology 113 (1997) 1465-1473
71. Akobeng A., and Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 1 (2005) CD003715.
72. Lochs H., Mayer M., Fleig W., et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 118 (2000) 264-273
73. Smith R., Rhodes J., Heatley R., et al. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut 19 (1978) 606-610
74. Shepherd H., Barr G., and Jewell D. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 8 (1986) 154-159
75. Greenberg G., Feagan B., Martin F., et al., for the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 331 (1994) 836-841
76. Thomsen O., Cortot A., Jewell D., et al., for the International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med 339 (1998) 370-374
77. Sandborn W., Lofberg R., Feagan B., Hanauer S., Campieri M., and Greenberg G. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 100 (2005) 1780-1787
78. Sutherland L., Singleton J., Sessions J., Hanauer S., Krawitt E., Rankin G., et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32 (1991) 1071-1075
79. Steinhart A., Feagan B., Wong C., et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123 (2002) 33-40
80. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108 (1995) 1617-1621
81. Pearson D., May G., Fick G., and Sutherland L. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 123 (1995) 132-142
82. Ardizzone S., Maconi G., Sampietro G., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 (2004) 730-740
83. Hanauer S., Korelitz B., Rutgeerts P., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127 (2004) 723-729
84. Feagan B., Rochon J., Fedorak R., et al., for the The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 332 (1995) 292-297
85. Feagan B., Fedorak R., Irvine E., et al., for the North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 342 (2000) 1627-1632
86. Targan S., Hanauer S., van Deventer S., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
87. Hanauer S., Feagan B., Lichtenstein G., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
88. Present D., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
89. Sands B., Anderson F., Bernstein C., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
90. Hanauer S., Sandborn W., Rutgeerts P., Fedorak R., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 130 (2006) 323-333
91. Colombel J., Sandborn W., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
92. Sandborn W., Feagan B., Stoinov S., et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase III study (PRECiSE 1). Gastroenterology 130 (2006) A-107
93. Schreiber S., Khaliq-Kareemi M., Lawrance I., et al. Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (PRECISE). Gut 54 suppl VII (2005) A82
94. Kane S., Schoenfeld P., Sandborn W., Tremaine W., Hofer T., and Feagan B. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther 16 (2002) 1509-1517
95. Schoon E., Bollani S., Mills P., et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 3 (2005) 113-121
96. Moreland L., Bate G., and Kirkpatrick P. Abatacept. Nat Rev Drug Discov 5 (2006) 185-186
97. van Assche G., Sandborn W., Feagan B., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55 (2006) 1568-1574
98. Creed T., Norman M., Probert C., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18 (2003) 65-75
99. Travis S., Yap L., Hawkey C., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11 (2005) 713-719
100. Baumgart D., Hommes D., Reinisch W., et al. The phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with i.v. steroids (IVSR-UC). Gut 54 (2005) A57
101. Feagan B., Greenberg G., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N Engl J Med 352 (2005) 2499-2507
102. van Deventer S., Tami J., and Wedel M. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53 (2004) 1646-1651
103. van Deventer S., Wedel M., Baker B., Xia S., Chuang E., and Miner Jr. P. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23 (2006) 1415-1425
104. Miner Jr. P., Wedel M., Xia S., and Baker B. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 23 (2006) 1403-1413
105. Tilg H., Vogelsang H., Ludwiczek O., et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 52 (2003) 1728-1733
106. Nikolaus S., Rutgeerts P., Fedorak R., et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52 (2003) 1286-1290
107. Summers R., Elliott D., Urban Jr. J., Thompson R., and Weinstock J. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005) 825-832
108. Shimoyama T., Sawada K., Hiwatashi N., et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16 (2001) 1-9
109. Sawada K., Muto T., Shimoyama T., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
110. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
111. Schreiber S., Keshavarzian A., Isaacs K., et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132 (2007) 76-86
112. Sandborn W., Sands B., Wolf D., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 17 (2003) 1355-1364
113. Sinha A., Nightingale J., West K., Berlanga-Acosta J., and Playford R. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349 (2003) 350-357
114. Lemann M., Mary J., Colombel J., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2005) 1812-1818
115. Rutgeerts P., Diamond R., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
116. Hanauer S., Wagner C., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
117. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
118. Sandborn W., Fazio V., Feagan B., and Hanauer S. American Gastroenterological Association Clinical Practice C: AGA technical review on perianal Crohn's disease. Gastroenterology 125 (2003) 1508-1530
119. Rutgeerts P., Van Assche G., Vermeire S., et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128 (2005) 856-861
120. Sandborn W., Rutgeerts P., Enns R., Hanauer S., Colombel J., Kent J., and Pollack P. Adalimumab rapidly induces clinical remission and response in in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN trial. Am J Gastroenterol 101 (2006) S448
121. Schreiber S., Rutgeerts P., Fedorak R., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
122. Sandborn W., Feagan B., Radford-Smith G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 53 (2004) 1485-1493
123. Feagan B., Sandborn W., Lichtenstein G., Radford-Smith G., Patel J., and Innes A. CDP517, a humanized monoclonal antibody to tumor necrosis factor-a, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23 (2006) 617-628
124. Sandborn W., Hanauer S., Katz S., et al. Etanercept for Active Crohn's Disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
125. Rutgeerts P., Sandborn W., Fedorak R., et al. Onercept (recombinant human p55 tumor necrosis factor receptor) for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 888-893
126. Baumgart D., Hommes D., Reinisch W., et al. A phase I study: visilizumab therapy in Crohn's disease (CD) patients with perianal fistula. Gut 55 (2006) A136
127. Chaudhary R., Butler M., Playford R., and Ghosh S. Anti-TNF antibody induced stimulated T lymphocyte apoptosis depends on the concentration of the antibody and etanercept induces apoptosis at rates equivalent to infliximab and adalimumab at 10 micrograms per ml concentration. Gastroenterology 130 (2006) 1-696
128. Hommes D., Mikhajlova T., Stoinov S., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1131-1137
129. Fukuda Y., Takazoe M., Sugita A., et al. The treatment with an oral spherical adsorptive carbon (AST-120) improves anal fistula, PDAI and CDAI scores - A randomized double-blind placebo-controlled trial. Gastroenterology 130 (2006) A110
130. Hommes D., van den B., Plasse T., et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122 (2002) 7-14
131. Schreiber S., Feagan B., D'Haens G., et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 325-334
132. Vasiliauskas E., Kam L., Abreu-Martin M., et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117 (1999) 1278-1287
133. Ehrenpreis E., Kane S., Cohen L., Cohen R., and Hanauer S. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 (1999) 1271-1277
134. Mannon P., Fuss I., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
135. Burakoff R., Barish C., Riff D., et al. A Phase 1/2A Trial of STA 5326, an Oral Interleukin-12/23 Inhibitor, in Patients with Active Moderate to Severe Crohn's Disease. Inflamm Bowel Dis 12 (2006) 558-565
136. Ito H., Takazoe M., Fukuda Y., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996
137. Fedorak R., Gangl A., Elson C., et al., for the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 119 (2000) 1473-1482
138. Schreiber S., Fedorak R., Nielsen O., et al., for the Crohn's Disease IL-10 Cooperative Study Group. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 119 (2000) 1461-1472
139. Braat H., Rottiers P., Hommes D., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 754-759
140. Sands B., Winston B., Salzberg B., et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16 (2002) 399-406
141. Gordon F., Lai C., Hamilton M., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121 (2001) 268-274
142. Ghosh S., Goldin E., Gordon F., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
143. Sandborn W., Colombel J., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
144. Targan S., Feagan B., Fedorak R., et al. Natalizumab induces sustained response and remission in patients with active Crohn's disease: results from the ENCORE trial. Gastroenterology 130 (2006) A-108
145. Yacyshyn B., Chey W., Goff J., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51 (2002) 30-36
146. Yacyshyn B., Chey W., Wedel M., Yu R., Paul D., and Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5 (2007) 215-220
147. Korzenik J., Dieckgraefe B., Valentine J., Hausman D., and Gilbert M. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005) 2193-2201
148. Belluzzi A., Brignola C., Campieri M., Pera A., Boschi S., and Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 334 (1996) 1557-1560
149. Slonim A., Bulone L., Damore M., Goldberg T., Wingertzahn M., and McKinley M. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 342 (2000) 1633-1637
150. Lugering A., Schmidt M., Lugering N., Pauels H., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
151. Reinisch W., Hommes D., van Assche G., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1138-1144
152. Yousry T., Major E., Rysckewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephaolopathy. N Engl J Med 354 (2006) 924-933
153. Present D., Meltzer S., Krumholz M., Wolke A., and Korelitz B. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649
154. Connell W., Kamm M., Ritchie J., and Lennard-Jones J. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34 (1993) 1081-1085
155. Kandiel A., Fraser A., Korelitz B., Brensinger C., and Lewis J. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
156. Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 55 (2006) 1198-1206
157. Bongartz T., Sutton A., Sweeting M., Buchan I., Matteson E., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
158. Lichtenstein G., Feagan B., Cohen R., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
159. Bernstein C., Blanchard J., Kliewer E., and Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
160. Loftus Jr. E., Harewood G., Loftus C., et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54 (2005) 91-96
161. Velayos F., Terdiman J., and Walsh J. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
162. Collins P., Mpofu C., Watson A., and Rhodes J. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2 (2006) CD000279.
163. Palascak-Juif V., Bouvier A., Cosnes J., et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 11 (2005) 828-832